In the realm of medical AI, China and the United States are currently on divergent paths. Over the past six months, the financing scale and market valuations of US tech firms operating in the medical AI sector have witnessed a steady ascent. Conversely, domestic medical IT companies, exemplified by Wining and Chuangye Huikang, have encountered losses and a downturn in their market capitalizations.

Domestic startups are attempting to adapt the US AI medical model for 'localized' applications. However, it's worth noting that the valuations of US AI medical companies might be overinflated. At the operational level, domestic medical IT companies exhibit similar scenarios and converging technologies. The primary disparities between them and their US counterparts lie in doctor practices and payer systems, factors that constrain their valuations. In the near term, there's a possibility of further decline in valuation ranges.

Although OpenEvidence holds a technological edge, its model is susceptible to replication, prompting it to expand its B-end business through strategic collaborations. Meanwhile, domestic medical IT companies are undergoing a phase of rapid AI technology evolution. Despite their absence from the pharmaceutical and medical device payment segments, they are poised to capitalize on opportunities across different epochs of medical AI to achieve 'payment based on results.' A new landscape in this field may well emerge within the next 1-2 years.